Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) headquartered in Berkeley Heights, will host a conference call for the investment community to discuss the 2Q20 financial results on 12th August 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.cyclacel.com
Earnings Expectation
Cyclacel Pharmaceuticals, Inc. is reporting second quarter financial results on Wednesday 12th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, CYCC is expected to report 2Q20 loss of $ 0.47 per share. For the full year, analysts anticipate loss of $ 2.54 per share bottom line.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The companys oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia.
